Filing excerpt
In the first quarter of 2026, we recorded a charge of $101.9 million for acquired IPR&D, primarily in connection with our acquisition of certain rights to an antibody from a privately held biotechnology company.
Source: Autobound Signal API · 94 signals tracked for Regeneron · updated
Get Regeneron's live signals in Claude or ChatGPT, or by API
What changed at Regeneron this week? Use Autobound signals for regeneron.com.The company is actively acquiring external innovation, spending over $100M on in-process R&D from another biotech firm.
Filing excerpt
In the first quarter of 2026, we recorded a charge of $101.9 million for acquired IPR&D, primarily in connection with our acquisition of certain rights to an antibody from a privately held biotechnology company.
What this signalsFilings often name leadership changes, deals and spending plans.
Technologies
sec-10qcapexIncreaseGet every 10-Q signal for Regeneron and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Regeneron this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/5879f527-b421-44bd-9241-fac4eb77d02d returns this record as JSON. POST /v1/companies/enrich returns every signal for regeneron.com.
{
"signal_id": "5879f527-b421-44bd-9241-fac4eb77d02d",
"signal_type": "sec-10q",
"signal_subtype": "capexIncrease",
"detected_at": "2026-05-05T08:48:22.099+00:00",
"company": {
"name": "Regeneron",
"domain": "regeneron.com"
},
"data": {
"detail": "The company is actively acquiring external innovation, spending over $100M on in-process R&D from another biotech firm. This signals an ongoing strategy of growth through acquisition, creating opportunities for M&A advisory, legal, and technology integration services.",
"metrics": {
"timeframe": "current_quarter",
"dollar_context": "Acquired in-process research and development (IPR&D)",
"dollar_millions": 101.9
},
"summary": "Regeneron spends $101.9M in Q1 to acquire new antibody technology",
"excerpts": "In the first quarter of 2026, we recorded a charge of $101.9 million for acquired IPR&D, primarily in connection with our acquisition of certain rights to an antibody from a privately held biotechnology company.",
"relevance": 0.8,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/872589/000087258926000016/regn-20260331.htm",
"filing_date": "2026-04-29",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "03/31",
"sales_relevance": "Budget available",
"signal_category": "financial",
"technologies_mentioned": [
"antibody"
]
}
}
curl https://signals.autobound.ai/v1/signals/5879f527-b421-44bd-9241-fac4eb77d02d \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"regeneron.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.